<DOC>
	<DOC>NCT02423980</DOC>
	<brief_summary>This is an open-label, exploratory pilot study in patients with T1D. The study will involve two daytime clinical research center visits 7-14 days apart. Subjects will receive a single injection of G-Pen™ (glucagon injection) at each visit.</brief_summary>
	<brief_title>G-Pen™ for Hypoglycemia Rescue in T1D</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Type 1 diabetes mellitus for at least 24 months Pregnant or Lactating HbA1c &gt;10.5% at screening Use of &gt; 2.0 U/kg total insulin dose per day Inadequate bilateral venous access in both arms Renal insufficiency Congestive heart failure, NYHA class II, III or IV Active malignancy within 5 years from screening Major surgical operation within 30 days prior to screening Seizure or bleeding disorder Glycogen storage disease Active substance or alchohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>